Our proprietary gene therapy device platform, encapsulated cell biodelivery (ECB), targets the brain directly with powerful protein therapeutics. Using minimally invasive surgery, slender EC-devices can be introduced into diseased areas of the brain where the permeable distal tip secretes therapeutic protein(s) synthesized by an encapsulated engineered cell line.
The cells have been shown to survive and secrete for a year or longer, a sufficient amount of time for diseased brain cells to recover function. EC devices can produce biologics such as neurotransmitters, small peptides, enzymes, growth factors, and antibodies. They are also capable of secreting multiple protein therapeutics simultaneously, opening the door for novel disease targeting.